|
|
Article: FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder.
- Article from:
- PR Newswire
- Article date:
- March 1, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MADISON, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced today that the U.S. Food and Drug Administration (FDA) has approved PRISTIQ(TM) (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD). Wyeth expects to begin shipping PRISTIQ to wholesalers beginning in the second quarter of 2008.
"We are pleased to be able to bring PRISTIQ to patients," says Bernard Poussot, President and Chief Executive Officer of Wyeth. "PRISTIQ is Wyeth's fourth new drug to receive approval in the last twelve months, demonstrating ...